DoH Policies screened during the period: 1 July 2016 to 30 September 2016
Topics:
Date published:
In fulfilling its obligations under Section 75 the Department is required to equality screen all of its policies and services under consideration to determine whether they should be subject to a full equality impact assessment (EQIA).
Documents
- NICE Clinical Guideline NG47 - Haematological cancers: improving outcomes
- NICE Technology Appraisal TA397 - Belimumab for the treatment of active autoantibody-positive systemic lupus erythematosus
- NICE Technology Appraisal TA396 - Trametinib in combination with dabrafenib for treating advanced (unresectable or metastatic) melanoma
- NICE Technology Appraisal TA395 - Ceritinib for previously treated anaplastic lymphoma kinase-positive non-small-cell lung cancer
- NICE Technology Appraisal TA394 - Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
- NICE Technology Appraisal TA393 - Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
- NICE Technology Appraisal TA392 - Adalimumab for treating moderate to severe hidradenitis suppurativa
- NICE Clinical Guideline CG98 - Jaundice in newborn babies under 28 days – Addendum
- NICE Public Health Guideline – PH52 - Needle and syringe programmes
- NICE Technology Appraisal TA399 - Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts
- NICE Technology Appraisal TA398 - Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation
- NICE Public Health Guideline – PH54 - Physical activity: exercise referral schemes
- NICE Clinical Guideline NG50 - Cirrhosis in over 16s assessment and management
- NICE Technology Appraisal - TA 400 - Nivolumab in combination with ipilimumab for treating advanced melanoma
- NICE Clinical Guideline NG49 - Non-alcoholic fatty liver disease (NAFLD) assessment and management
- NICE Technology Appraisal TA403 - Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer
- NICE Clinical Guideline NG52 - Non-Hodgkin’s lymphoma: diagnosis and management
- NICE Clinical Guideline NG51 - Sepsis: recognition, diagnosis and early management
- NICE Technology Appraisal TA402 - Pemetrexed maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer (review of TA309)
- NICE Technology Appraisal TA401 - Bosutinib for previously treated chronic myeloid leukaemia (Review of TA299)
- NICE Technology Appraisal TA404 - Degarelix for treating advanced hormone-dependent prostate cancer
- NICE Public Health Guideline PH53 - Weight management: lifestyle services for overweight or obese adults
- NICE Technology Appraisal TA405 - Trifluridine–tipiracil for previously treated metastatic colorectal cancer
- General Dental Services (Amt) Regulations (NI) 2016
- Protect Life 2 – A Strategy for suicide prevention in the north of Ireland
- Amendments to the Pharmaceutical Services Regulations (NI) 1997